References
- Fozard J. R. 5-HT3 receptors and cytotoxic drug-induced vomiting. Trends Pharmacol Sci 1987; 8: 44–45
- Andrews P. L. R., Rapeport W. G., Sanger G. J. Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci 1988; 9: 334–341
- Cubeddu L. X., Hoffmann I. S., Fuenmayor N. T., Finn A. L. Efficacy of ondansetron (GR38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N EnglJ Med 1990; 322: 810–816
- Costall B., Domenay A. M., Naylor R. J., Tattersal F. O. 5-hydroxy-tryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacol 1986; 25: 959–961
- Hawthorn J., Ostler K. J., Andrews P. L. R. The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cisplatin in the ferret. Quarterly J Exper Physiol 1988; 73: 7–21
- Wampler G. The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis. Drugs 1983; 25(Suppl 1)35–51
- Edge S. B., Funkhouser W. K., Berman A., et al. High-dose oral and intravenous metoclopramide in doxorubicin/cy-clophosphamide-induced emesis. Am J Clin Oncol 1987; 10: 257–263
- De Haan L. D., De Mulder P. H. M., Beex L. V. A. M., Debrupuyne F. M. J., Challoner T., De Pauw B. E. The efficacy of GR38032F, an antagonist of 5-Hydroxytriptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting. Eur J Clin Oncol 1988; 24: 1383–1384
- De Mulder P. H. M., Seynaeve C., Vermorken J. B., et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990; 113: 834–840
- Einhorn L. H., Nagy C., Werner K., Finn A. L. Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol 1990; 8: 731–735
- Grunberg S. M., Stevenson L. L., Russel C. A., MCDermed J. E. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1989; 7: 1137–1141
- Hesketh P. J., Murphy W. K., Lester E. P., et al. GR38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 1989; 7: 700–705
- Kris M. G., Gralla R. J., Clark R. A., Tyson L. B. Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J Natl Cancer Inst 1989; 81: 42–46
- Marty M., Pouillart P., Scholl S., et al. Comparison of the 5-hydroxytryptamine-3 (serotonin) antagonist ondansetron (GR38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990; 322: 816–821
- Priestman T. J. Clinical studies with ondansetron in the control of radiation-induced emesis. Eur J Cancer Clin Oncol 1989; 25(Suppl 1)S29–S33
- Carden P. A., Mitchell S. L., Waters K. D., et al. Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia. J Clin Oncol 1990; 8: 1531–1535
- Viner C. V., Selby P. J., Zulian G. B., et al. Ondansetron-a new safe and effective antiemetic in patients receiving high-dose melphalan. Cancer Chemother Pharmacol 1990; 25: 449–453
- Croockewit S., Schattenberg A., De Witte T., Lane-Allman E. Ondansetron is an effective prophylactic antiemetic drug in patients undergoing allogeneic bone marrow transplantation. XVII Meeting EBMT, Cortina. 1991, (abstract no 81)
- Croockewit S. The efficacy of ondansetron in emesis induced by total body irradiation (abstract). Zofran (Ondansetron). Satellite Symposium. Copenhagen Falkoner Center, 1990; 15–17
- Pimentel P. (abstract). Eur J Cancer 1991; 27(Suppl 2)S299
- Vellek M., Brown R. Evaluation of ondansetron in preparative regimens for bone marrow transplantation: a pilot study (abstract). Blood 1991; 78(Suppl 1)817A
- Hewitt M., Cornish J., Pamphillon D., Oakhill A. Effective emetic control during conditioning of children for bone marrow transplant using ondansetron, a 5HT-3 antagonist. Bone Marrow Transpl 1991; 7: 431–433